AbCellera Biologics Inc. ABCL Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s stock-based comp?
- AbCellera Biologics Inc. (ABCL) reported stock-based comp of $12.01M in Q1 2026.
- How has AbCellera Biologics Inc.'s stock-based comp changed year-over-year?
- AbCellera Biologics Inc.'s stock-based comp decreased by 18.8% year-over-year, from $14.79M to $12.01M.
- What is the long-term trend for AbCellera Biologics Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s stock-based comp has grown at a 16.2% compound annual growth rate (CAGR), from $30.65M to $55.79M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.